Suppr超能文献

吡格列酮和二甲双胍对2型糖尿病合并非酒精性脂肪性肝病患者视黄醇结合蛋白-4和脂联素的影响

Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases.

作者信息

Yang Lu, Song Mei-qing, Zhang Qiu-ling, Shou Lan, Zang Shu-fei, Yang Yan-li

机构信息

Department of Endocrinolgy,Affliated Hospital of Hangzhou Normal University,Hangzhou 310015,China.

出版信息

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Jun;36(3):309-12. doi: 10.3881/j.issn.1000-503X.2014.03.015.

Abstract

OBJECTIVE

To compare the effects of piglitazone and metformin on retinol-binding protein-4 (RBP-4) and adiponcetin (APN) in patients with type 2 diabetes mellitus (T2DM) complicated with Non alcohol fatty acid liver disease (NAFLD).

METHODS

Totally 60 T2DM patients complicated with NAFLD were equally and randomly divided into pioglitazone group and metform group. The levels of biochemical indicators including body mass index (BMI), glucose hemoglobin A1C (GHbA1C), insulin resistance (HOMA-IR), fasting blood glucose (FBG), fasting insulin (FIns), and serum triglycerides (TG) as well as serum RBP-4 and APN level were measured pre-treatment and 12 weeks after treatments.

RESULTS

After 12 weeks of treaments, BMI, FBG, HOMA-IR, GHbA1C, FIns, and TG decreased (all P<0.05) in both piglitazone group and metform group. APN increased (all P<0.05) in both groups. RBP-4 decreased (P<0.05) in piglitazone group. Compare with the metform group, the levels of RBP-4, FIns ,and HOMA-IR decreased and BMI increased in piglitazone group (P<0.05).

CONCLUSION

Piglitazone is superior to metoform in decreasing RBP-4 level and HOMA-IR in patients with T2DM complicated with NAFLD.

摘要

目的

比较吡格列酮与二甲双胍对2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者视黄醇结合蛋白4(RBP - 4)和脂联素(APN)的影响。

方法

将60例T2DM合并NAFLD患者平均随机分为吡格列酮组和二甲双胍组。在治疗前及治疗12周后测量包括体重指数(BMI)、糖化血红蛋白A1C(GHbA1C)、胰岛素抵抗(HOMA - IR)、空腹血糖(FBG)、空腹胰岛素(FIns)、血清甘油三酯(TG)等生化指标以及血清RBP - 4和APN水平。

结果

治疗12周后,吡格列酮组和二甲双胍组的BMI、FBG、HOMA - IR、GHbA1C、FIns和TG均降低(均P<0.05)。两组的APN均升高(均P<0.05)。吡格列酮组的RBP - 4降低(P<0.05)。与二甲双胍组相比,吡格列酮组的RBP - 4、FIns和HOMA - IR水平降低,BMI升高(P<0.05)。

结论

在降低T2DM合并NAFLD患者的RBP - 4水平和HOMA - IR方面,吡格列酮优于二甲双胍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验